Document is current
Any future updates will be listed below
-
Authors
Zhang, Yi https://orcid.org/0000-0002-7453-6188
Xiang, Guanjue https://orcid.org/0000-0003-1328-7197
Jiang, Alva Yijia
Lynch, Allen
Zeng, Zexian
Wang, Chenfei https://orcid.org/0000-0001-7573-3768
Zhang, Wubing
Fan, Jingyu https://orcid.org/0000-0003-2440-2015
Kang, Jiajinlong
Gu, Shengqing Stan
Wan, Changxin
Zhang, Boning
Liu, X. Shirley
Brown, Myles https://orcid.org/0000-0002-8213-1658
Meyer, Clifford A. https://orcid.org/0000-0002-8321-2839
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01CA163222)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01HG011139)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA237617)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 27 July 2022
Accepted: 26 April 2023
First Online: 6 May 2023
Competing interests
: MB is a consultant to and receives sponsored research support from Novartis. MB serves on the SAB of H3 Biomedicine, Kronos Bio, FibroGen, and GV20 Therapeutics. X.S.L conducted the work while being on the faculty at DFCI, and is currently a board member and CEO of GV20 Therapeutics. The remaining authors declare no competing interests.
